Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy by Trendowski, Matthew R. et al.
Clinical and Genome-Wide Analysis of Serum Platinum Levels 
after Cisplatin-Based Chemotherapy
Matthew R. Trendowski1,*, Omar El Charif1,*, Mark J. Ratain1, Patrick Monahan2, Zepeng 
Mu1, Heather E. Wheeler3, Paul C. Dinh Jr2, Darren R. Feldman4, Shirin Ardeshir-Rouhani-
Fard2, Robert J. Hamilton5, David J. Vaughn6, Chunkit Fung7, Christian Kollmannsberger8, 
Taisei Mushiroda9, Michiaki Kubo9, Robyn Hannigan10, Frederick Strathmann11, Lawrence 
H. Einhorn2, Sophie D. Fossa12, Lois B. Travis2,#, M. Eileen Dolan1,#
1Department of Medicine, University of Chicago, Chicago, IL, USA
2Department of Medical Oncology, Indiana University, Indianapolis, IN
3Departments of Biology and Computer Science, Loyola University Chicago, Chicago, IL, USA
4Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA, NY
5Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada
6Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
7J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
8Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
9RIKEN Center for Integrative Medical Science, Yokohama, Japan
10School for the Environment, University of Massachusetts Boston, Boston, MA
11NMS Labs, 3701 Welsh Road, Willow Grove, PA 19090
12Department of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway
Abstract
Purpose: Serum platinum is measurable for years after completion of cisplatin-based 
chemotherapy (CBC). We report the largest investigation of serum platinum levels to date of 1,010 
testicular cancer survivors (TCS) assessed 1-35 years after CBC and evaluate genetic contributions 
to these levels.
Experimental Design: Eligible TCS given 300 or 400 (±15) mg/m2 cisplatin underwent 
extensive audiometric testing, clinical examination, completed questionnaires and had crude serum 
platinum levels measured. Associations between serum platinum and various risk factors and 
toxicities were assessed after fitting a bi-exponential model adjusted for follow-up time and 
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cumulative cisplatin dose. A genome-wide association study (GWAS) was performed using the 
serum platinum residuals of the dose and time-adjusted model.
Results: Serum platinum levels exceeded the reference range for approximately 31 years, with a 
strong inverse relationship with creatinine clearance at follow-up (age-adjusted p = 2.13×10−3). 
We observed a significant, positive association between residual platinum values and luteinizing 
hormone (age-adjusted p=6.58×10−3). Patients with high residual platinum levels experienced 
greater Raynaud’s phenomenon than those with medium or low levels (age-adjusted ORhigh/low = 
1.46; p = 0.04), as well as a higher likelihood of developing tinnitus (age-adjusted ORhigh/low = 
1.68, p = 0.07). GWAS identified one single nucleotide polymorphism (SNP) meeting genome-
wide significance rs1377817 (p=4.6×10−8, a SNP intronic to MYH14).
Conclusions: This study indicates that residual platinum values are correlated with several 
cisplatin-related toxicities. One genetic variant is associated with these levels.
Introduction
Advances in chemotherapy have markedly improved overall cancer survival, enabling more 
patients to live decades after completion of chemotherapeutic treatments. However, survivors 
often suffer from severe off-target toxicities due to chemotherapy. These toxicities can limit 
clinical use, compromise efficacy, and many can permanently impact survivors’ quality of 
life. As the number of long-term cancer survivors has continued to increase, the health and 
financial burdens associated with chemotherapy-induced adverse sequelae have become 
increasingly prevalent (1–3).
This clinical problem is exemplified by cisplatin, a widely used platinating agent that is 
effective against several adult-onset and pediatric malignancies. High five-year relative 
survival rates follow cisplatin-based therapy for a number of tumors (4), including testicular 
cancer (95%), hepatoblastoma (> 80%), medulloblastoma (70-80%), and osteosarcoma 
(60-80%). Unfortunately, cisplatin also elicits a number of debilitating side effects, including 
ototoxicity, neurotoxicity, nephrotoxicity, cardiometabolic toxicities, and secondary 
malignancies (5, 6). These toxicities can be progressive and irreversible, leading to chronic 
health conditions in young cancer survivors. For example, approximately 18% of adults (7) 
and 7-22% of children (8) are left with severe to profound of hearing loss. In addition, 
56.2% of testicular cancer survivors given a median dose of 400 mg/m2 report symptoms of 
sensory neuropathy at a median of 5 years after treatment, with 12.5% reporting severe 
symptoms (9). Reduced renal function is also detected in 25-35% of patients after one 
cisplatin dose (10). While the majority of patients fully recover from the initial onset of 
nephrotoxicity, both progressive and irreversible nephrotoxicity have been reported (11, 12).
Several studies have shown detectable tissue platinum (13) and platinum-DNA adducts (14) 
years after cisplatin therapy. A 13-28 year follow-up study demonstrated that circulating 
platinum persisted for decades after treatment (15). Serum platinum levels have been shown 
to remain up to 1,000 times higher than normal for 20 years after completion of therapy (15–
18). One study demonstrated that about 10% of circulating serum platinum remains reactive 
(19).
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Circulating platinum has been evaluated for its contribution to the severity and persistence of 
cisplatin-induced neurotoxicity (paresthesias, neuropathy, and Raynaud’s phenomenon), 
nephrotoxicity, and ototoxicity (hearing loss and tinnitus). Inconsistent associations have 
been found between serum platinum levels and cisplatin-induced toxicities. Sprauten et al. 
(20) identified significant associations between crude serum platinum levels (defined as total 
platinum concentration) and symptoms of paresthesias, Raynaud’s phenomenon, and tinnitus 
in 169 testicular cancer survivors (TCS). Hjelle et al. (17) found crude serum platinum levels 
to be significantly associated with tinnitus and elevated concentrations of luteinizing 
hormone (LH), but not with paresthesias and Raynaud’s phenomenon in 292 TCS after 
adjusting for cisplatin dose. A study that longitudinally assessed 77 TCS regarding declines 
in crude serum platinum levels and toxicities counter-intuitively showed larger declines in 
platinum levels related to worsening of tinnitus and hand paresthesias (15), perhaps because 
larger declines are correlated with less time since treatment. Importantly, none of these 
studies accounted for the kinetics of metabolism and clearance by accounting for variance in 
time since treatment. A longitudinal pharmacokinetic study serially measuring serum and 
urine platinum found associations of area-under-the-platinum-exposure-curve with 
neuropathy, but not tinnitus or Raynaud’s phenomenon, and noted new associations with 
hypertension, hypercholesterolemia, and hypogonadism (21). This study, however, had a 
relatively small sample size (n = 99 TCS) and did not compare platinum exposure to an 
unexposed control group.
In this study, we evaluate clinical correlates with serum platinum levels after constructing a 
dose- and follow-up time-adjusted pharmacokinetic model in a cohort of 1,010 TCS 
characterized for variables on diagnosis, treatment, medical history, lifestyle and behavioral 
factors, and comorbidities over a wide range of follow-up periods (1-35 years). We then use 
the model to examine the association between serum platinum levels and late adverse events 
associated with cisplatin toxicity. In addition, we perform a genome-wide association study 
(GWAS) to assess genetic contributions to our phenotype derived from serum platinum 
levels.
Patients and Methods
Patients and Data Collection.
All patients were enrolled in The Platinum Study, a cross-sectional study including eight 
cancer centers in the United States and Canada (5). Eligibility criteria were previously 
described (9, 22). Briefly, during routine follow-up, eligible TCS underwent physical 
examination/phlebotomy and completed questionnaires as well as blood collection for serum 
platinum levels. Data relating to germ cell tumor diagnosis and treatment were abstracted 
from medical records using standardized forms described previously (23). All abstractors 
participated in centralized, in-person training (23). Study procedures were approved by the 
Human Subjects Review Board at each institution, and all patients provided written consent 
for participation in study procedures, including genetic analyses. The studies were 
conducted in accordance with recognized ethical guidelines (U.S. Common Rule).
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Serum Platinum Quantification.
The concentration of serum platinum was quantified in two batches. For the first batch, 50 
μL of serum at 10x dilution were aliquoted into 96-well plates, and a low-volume 
autosampler (Teledyne Technologies, Thousand Oaks, CA) introduced aliquots into an 
Agilent 7900 for inductively coupled plasma mass spectrometry [ICP-MS] (Agilent 
Technologies, Santa Clara, CA). For the second set, samples were diluted 10x and measured 
on the NexION 2000C for ICP-MS. Both batches utilized an iridium internal standard for 
calibration. Seven non-zero calibration standards ranging from 0.01 ng/L to 100 ng/L of Pt, 
spiked with 20 ng/L iridium for internal standardization, were analyzed every 10 samples 
with weighted linear regression (1/standard deviation of triplicate sample readings as 
weight-factor). Linearity of calibrations was 0.9999 ± 0.0001. Method detection limit for 
platinum (NexIon 2000C) was 0.006 ng/L following Long and Winefordner (24). Lower 
limit of quantification (LLOQ) was 0.010 ng/L translating to an absolute LLOQ of 1 pg Pt. 
Carry-over was measured from blanks analyzed post-analysis of 100 ng/L standard (Greater 
Limit of Quantification) and a 35-s rinse with measured blanks below method detection 
limit. All samples were analyzed in a single day so no inter-day variation is noted. Within 
day analytical accuracy was determined by comparison of measured replicates of human 
serum (NIST 909c) spiked with a known amount platinum (5 ng/L) resulting in % error of 
0.02. Precision, based on standard deviation of triplicate analyses of samples and standards 
was better than 0.025 (relative standard deviation, 0.17%).
To evaluate inter-batch consistency, 50 samples were measured using both methods and 
produced a correlation coefficient of 0.94. Batches were therefore combined for analysis and 
the mean value of duplicates was taken following data normalization. The greater limit of 
quantification of both methods was used (5 ng/L), and the nonparametric reference interval 
for serum platinum that was previously established based on 147 non-platinum treated 
patient samples was used (25). This was determined as the 2.5th-97.5th percentile of 147 
non-platinum treated serum samples (22).
Pharmacokinetic Modeling.
Given the cross-sectional study design, we constructed a bi-exponential model accounting 
for time since treatment completion and cumulative cisplatin dose. Most patients received a 
cumulative cisplatin dose of 300 or 400 mg/m2. Adding a 15 mg/m2 margin enabled the 
inclusion of an additional 56 patients (5.5%). Therefore, we treated dose as a dichotomous 
variable of 300±15 or 400±15 mg/m2 and excluded remaining patients (n=55). Prior to 
model fitting, cumulative cisplatin dose was taken into account by multiplying the serum 
platinum levels of 400±15 mg/m2 patients by 0.75, enabling normalization to those who 
received 300±15 mg/m2. We fit the following bi-exponential model to serum platinum 
levels:
serum platinum = Ae‐αt + Be‐βt
where A, α, B, and ß are parameters to be estimated in the bi-exponential model, and t is 
years since treatment completion. Multiplicative residuals were calculated by dividing the 
observed serum platinum values by values expected from the fitted bi-exponential model, 
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which were then log-transformed for normalization. These residuals are referred to as the 
residual platinum value. We also generated an ordinal version of residual platinum values by 
stratifying values based on their deviation from the mean to create three levels: “medium” 
(regression residuals = 0 ± 1 standard deviation [SD]), “low” (residuals < −1 SD), and 
“high” (residuals > 1 SD).
Patient-Reported Outcomes and Medical Records Data Abstraction.
As previously described (7, 23), patients completed questionnaires ascertaining neurotoxic 
and other symptoms, lifestyle habits, comorbidities, and medication use. Participant 
responses to questionnaires were mapped to individual adverse health outcomes and graded 
according to severity on a 0 to 4-point scale using a modified version of the National Cancer 
Institute Common Terminology Criteria for Adverse Events (version 4.03) as in prior studies 
(23, 26, 27). The cumulative burden of morbidity (CBM) score for cisplatin-induced 
toxicities was discerned by using adverse health outcomes previously related to cisplatin 
exposure (i.e., peripheral sensory neuropathy, hearing damage, tinnitus, and kidney disease) 
using a modified version described by Kerns et al (23) that removed autonomic neuropathy.
Peripheral sensory neuropathy was evaluated as previously described using nine items in the 
EORTC-CIPN20. Briefly, an ordinal (0-3) scale was constructed after taking the mean of 
symptom severity: 0 for “none”, 1 for “a little”, 2 for “quite a bit”, and 3 for “very much.” 
Groups 2 and 3 were combined. Raynaud’s phenomenon and tinnitus were evaluated with 
the validated Scale for Chemotherapy-Induced Neurotoxicity as previously described (28). 
Hearing loss was measured by extensive quantitative audiometry as previously described (7). 
Briefly, measured hearing thresholds in frequencies that showed statistically significant 
dose-response relationships with cumulative cisplatin dose (4-12 kHz) were geometrically 
averaged and rank normalized from age matched controls reported by Engdahl et al., (29) 
before testing for genetic associations (22). Hypogonadism was defined as testosterone 
levels ≤ 3 ng/mL based on crude measurement or whether the patient was on testosterone 
therapy. All patients who had testosterone levels > 3 ng/mL and were not on testosterone 
therapy were labeled as normal or high, and were grouped together as controls for the linear 
regression analysis, as previously described (30).
We defined lifestyle habits based on patient responses to The Platinum Study questionnaire, 
as previously described (9). Briefly, alcohol consumption was assessed as the response to the 
question “During the past year, how many drinks of alcoholic beverage have you consumed 
on average? (1 drink = 12 oz. beer [1 can or bottle], 4 oz. glass of wine, 1 mixed drink or 
shot of liquor)” with the following options: Rarely/never (0), 1-3/month (1), 1/week (2), 2-4/
week (3), 5-6/week (4), 1/day (5), 2-3/day (6), 4-5/day (7), and 6+/day (8). Tobacco use was 
assessed as the response to the following two questions: “Have you ever smoked cigarettes?” 
with “Yes” (1) and “No” (0) options and “Do you currently smoke cigarettes?”
Statistical Analysis.
The residual platinum value was treated both continuously and ordinally (low, medium, and 
high, based on the deviation from the mean). Simple and multiple linear regressions were 
used to evaluate associations between the continuous residual platinum values (dependent 
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variable) and comorbidities and risk factors. Simple and age-adjusted multinomial logistic 
regressions were used when residual platinum values were specified ordinally, with low 
residual platinum values designated as the reference group. When conceptually appropriate, 
age at diagnosis was added as a covariate. All statistical models were fit using R version 
3.3.2 (http://www.R-project.org/). Statistical significance was set at p < 0.05.
Genotyping and Genome-Wide Association Study.
DNA was extracted from peripheral blood. Genotyping was performed on the 
HumnaOmniExpressExome chip (Set 1 was genotyped on the 
HumanOmniExpressExome-8v1-2_A chip; set 2 was genotyped on the 
InfiniumOmniExpressExome-8v1-3_A chip; Illumina, San Diego, CA) at the RIKEN Center 
(Yokohama, Japan) as previously described (9, 22). Sample-level quality control (QC) 
criteria included: sample call rate > 0.99, pairwise identity by descent < 0.125, coefficient of 
inbreeding F < 6 standard deviations from the mean, and genetically European as determined 
by principal component analysis (performed using SMARTPCA). Single nucleotide 
polymorphism (SNP)-level QC included: call rate > 0.99, and Hardy-Weinberg equilibrium 
(Chi-squared P < 1 × 10−6). Imputation was done on the University of Michigan Imputation 
Server. SNPs and samples passing QC criteria comprised the input set for imputation with 
EAGLE phasing, performed on the Michigan Imputation Server using the Haplotype 
Reference Consortium (31–33). GWAS assumed linear additive SNP effects and was 
adjusted for age at diagnosis and the first 10 genetic principal components. Significance was 
set to p ≤ 5 × 10-8. Following GWAS, coding genes (n = 18,741) were annotated with the p-
value of the most significant SNP in the gene or within 25 kilobases (kb) using gencode v18. 
SNPs with imputation R2 < 0.8, MAF < 0.01, and INFO scores > 1.05 or < 0.3 were 
excluded. Only subjects who passed QC were included in the GWAS (Supplemental Figure 
1). Narrow-sense heritability was estimated with a genetic relationship matrix variance 
component model as implemented by GCTA with the same covariates as GWAS. The 
GWAS included 909 subjects with 7,305,641 SNPs.
Results
Cohort Characteristics.
Demographic and clinical characteristics for the entire cohort of TCS, as well as for each 
residual platinum value category, are provided in Table 1 and Supplemental Table 1. The 
median age at diagnosis and evaluation was 31 (range: 15-54) years and 37 (range: 18-75) 
years, respectively. Patients were treated with the following regimens: BEP (bleomycin, 
etoposide, and cisplatin; 54.0%), EP (etoposide and cisplatin; 30%), VIP (etoposide, 
ifosfamide, and cisplatin; 2.5%), VeIP (vinblastine, ifosfamide, and cisplatin; 0.1%), and 
other (unspecified cisplatin-based chemotherapy; 13.4%). Of the 1,010 TCS, 436 and 574 
(43.2% and 56.8%, respectively) were treated with 300±15 and 400±15 mg/m2 cisplatin, 
respectively. Median follow-up time was 4.5 years (range 1-35 years).
Pharmacokinetic Analysis.
Median serum platinum concentration was 309 ng/L (range 7.2-8,252 ng/L; 259 ng/L 
6.7-8,252 ng/L after normalization). Only 62 survivors (6.1%) had serum platinum 
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concentrations below 47 ng/L, the upper limit of the normal range determined from non-
platinum-treated patient samples. The median follow-up time for this group of survivors was 
19.5 years (range 6-31 years, 19.1 years for 300±15 mg/m2 and 20.3 years for 400±15 
mg/m2, respectively). Using bi-exponential regression, we estimated Cmax (concentration at 
time 0) to be 4,720 ng/L. We fit a bi-exponential model to the normalized serum platinum 
data (Figure 1A). Attempts to use a tri-exponential model resulted in a singular gradient 
error. When simulating the progression of the tri-exponential model fitting, the estimates for 
the tri-exponential parameters became unreasonably high, indicating that addition of the tri-
exponential parameters produced an overfitted model (data not shown). Consequently, it 
appeared that the two-compartment model was sufficient to model the decay of serum 
platinum over time.
The estimated time to reach the upper limit of the reference range was strikingly high (31 
years), and took nearly seven half-lives. Interestingly, the bi-exponential model never 
reached the seventh half-life of decay (serum platinum = 36.9 ng/L) over the course of 35 
years (the length of the longest follow-up period), indicating that patients are likely still at 
the upper limits of the reference interval nearly four decades after completion of cisplatin-
based chemotherapy. Because we could not compute concentration-time AUC with cross-
sectional data, we used the log-transformed multiplicative residuals from the fit of the bi-
exponential model to the normalized serum platinum data as the exposure phenotype and 
categorized survivors into low (n=118, 11.7%), medium (n=785, 77.7%), and high (n=107, 
10.6%) residual platinum values (Figure 1B and C). Importantly, residual platinum values 
were highly associated with normalized serum platinum levels obtained from the 1,010 
patients (p < 2×10−16), which was comparable to years since treatment completion (p < 
2×10−16), and more statistically significant than cumulative cisplatin dose (p = 0.09), weight 
(p = 0.23), BMI (p = 0.01), age at diagnosis (p = 0.05), age at clinical examination (p = 
6.92×10−15), or creatinine clearance (p = 0.04). Therefore, residual platinum values appear 
to be an accurate predictor of cisplatin clearance.
Predictors, Risk Factors, and Comorbidities.
We found a significant positive association between residual platinum values and age at 
diagnosis (p = 3.13×10−9), and a strong negative correlation between residual platinum 
values and creatinine clearance at follow-up (p = 1.99×10−5) (Figure 2A and B, Table 2). 
This association appears to persist years after cisplatin-based chemotherapy has been 
completed, as the association between residual platinum values and creatinine clearance 
remains statistically significant when only evaluating patients who last received cisplatin 
more than 15 years prior to clinical examination (n = 100; p = 0.01). We also found a 
significant positive association with LH levels (p = 6.07×10−3; Figure 2C, Table 2). 
Creatinine clearance and LH levels remained statistically significant after incorporating age 
at diagnosis as a covariate (Table 2). Hypogonadism was not significantly associated with 
residual platinum values (β = 0.07, p = 0.22, age-adjusted p = 0.75; Table 2). Hypertension, 
smoking, excess alcohol, and extent of physical activity were also not significantly 
associated with residual platinum values (p > 0.05, data not shown).
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We found significant positive associations between residual platinum values and several 
examined drug-induced toxicities, including the CBM score for cisplatin-induced toxicities 
(β = 0.04, p = 0.01), peripheral sensory neuropathy (β = 0.08, p = 7.52×10−3), and 
Raynaud’s phenomenon (β = 0.07, p = 9.84×10−3; Table 2). The association with Raynaud’s 
phenomenon remained statistically significant after adjusting for age at diagnosis (β = 0.05, 
p = 0.03), while the associations with CBM score (β = 0.02, p = 0.28) and peripheral sensory 
neuropathy (β = 0.04, p = 0.18) were no longer statistically significant. The association with 
Raynaud’s phenomenon also remained statistically significant after adjusting for both age 
and cumulative cisplatin dose (β = 0.05, p = 0.04). Tinnitus demonstrated a marginally 
significant association with residual platinum values (β = 0.07, p = 0.07, age-adjusted p = 
0.07, age and cisplatin dose-adjusted p = 0.07), but audiometric hearing thresholds were not 
statistically significant (β = 0.03, p = 0.21). Although audiometric hearing thresholds 
became statistically significant after adjusting for age at diagnosis (β = −0.05, p = 0.05), the 
β-value changed from positive to negative and by more than 10%, indicating that age at 
diagnosis is a negative confounder for the association.
We categorized patients into low, medium, or high residual platinum values to assess 
whether high levels of serum platinum were more associated with cisplatin-induced 
toxicities than medium or low levels (Supplemental Tables 2 and 3). In considering the 
severity of the toxicity, a higher proportion of patients who experienced more severe toxicity 
was demonstrated in the high residual platinum value group when compared to the low or 
medium groups for CBM score (Figure 3A), peripheral sensory neuropathy (Figure 3B) and 
Raynaud’s phenomenon (Figure 3C). In addition, patients with high residual platinum values 
were significantly more likely to have a higher CBM score (ORhigh/low = 1.26, p = 0.05), and 
peripheral sensory neuropathy (ORhigh/low = 1.61; p = 0.02, Supplemental Table 2), but not 
after adjusting for age (ORhigh/low = 1.13, p = 0.32 and ORhigh/low = 1.34; p = 0.17, 
respectively, Supplemental Table 3). Patients with high residual platinum values were 
significantly more likely to have Raynaud’s phenomenon (age-adjusted ORhigh/low = 1.46; p 
= 0.04, age and cisplatin dose-adjusted ORhigh/low = 1.45; p = 0.04). In regards to 
ototoxicity, patients with high residual platinum values had a higher likelihood of developing 
tinnitus (ORhigh/low = 1.69, p = 0.06), which remained marginally significant after adjusting 
for age at diagnosis (ORhigh/low = 1.68, p = 0.07), as well as age at diagnosis and cumulative 
cisplatin dose (ORhigh/low = 1.69, p = 0.07). Audiometric hearing thresholds were not 
significantly associated with high residual platinum values (ORhigh/low = 1.03, p = 0.86).
Genome-Wide Association Study.
GWAS of residual platinum values as a continuous variable identified one SNP that met 
genome-wide significance: rs1377817 (p = 4.6×10−8; Figure 4A). This SNP is intronic to 
MYH14, which encodes for a heavy chain of nonmuscle myosin 2. The SNP is in linkage 
disequilibrium with rs58754699 and rs113890379 (R2 = 1.0, p <0.0001), the next two most 
statistically significant genetic variants (p = 5.0×10−8 and 1.6×10−7, respectively). The SNP, 
rs1377817, explained 3.2% of the phenotype’s variance (p = 7.11×10−8). The Q-Q plot in 
Figure 4B indicates that the observed p-values of associated SNPs deviate significantly from 
the expected distribution (null hypothesis of no association) of p-values, suggesting that 
multiple SNPs are associated with the residual platinum value phenotype. Supplemental 
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Table 4 lists all SNPs associated with residual platinum values with p<0.0001. Using 
GCTA’s linear mixed model approach (34), we found that additive SNP effects did not 
explain phenotypic variance (h2 = 0.04 ± 0.38, p = 0.45).
Discussion
In this study, we uniquely interrogate exposure of serum platinum levels in a cohort of 1,010 
TCS following near uniform treatment with cisplatin-based chemotherapy and compare this 
with a platinum-unexposed control group. After normalizing serum platinum concentration, 
we fit a bi-exponential model with follow-up time as a variable. We define our measure of 
inter-patient variability in serum platinum as the observed serum platinum value divided by 
the expected value at the observed follow-up time derived from this model for each patient, 
followed by log-transformation. We postulate that this phenotype is correlated to the area 
under the concentration-time curve (AUC), which cannot be directly computed due to the 
cross-sectional study design. Our analytical method allows the interrogation of time-
dependent data without serial sampling. Although the AUC is not directly estimated, the 
multiplicative residual is theoretically proportional to dose-adjusted AUC, and thus is a 
plausible marker of cisplatin exposure. From this, we find that serum platinum levels exceed 
the reference range for approximately 31 years. This is consistent with previous findings 
indicating long-term detection of serum platinum, but to our knowledge this is the first study 
to provide an estimated time-to-reference range. We interrogate the association of platinum 
with toxicities beyond crude serum concentration measurements, the predominant analytical 
strategy previously used in studies evaluating the relationship of serum platinum levels and 
toxicities (15, 17, 20). We do so because associations between serum platinum levels and 
toxicological traits are likely confounded by follow-up time, the strongest predictor of serum 
platinum concentration. Our data suggest that patients with high serum platinum levels are 
more susceptible to developing tinnitus and Raynaud’s phenomenon than those with 
medium or low serum platinum levels, but does not provide robust associations with other 
toxicities, including cumulative burden of morbidity scores, hearing loss, and peripheral 
sensory neuropathy. We additionally perform a GWAS to determine the genetic variants 
associated with residual platinum values.
As expected, we found a strong negative association between chronic serum platinum 
exposure and creatinine clearance. Cisplatin is excreted through the renal route by 
glomerular filtration with some tubular secretion, and is also nephrotoxic (35). Therefore, 
we expect that lower pre-treatment creatinine clearance would contribute to higher chronic 
serum concentrations of platinum, as found by Boer et al. (21). In addition, we expect that 
ongoing exposure to higher chronic serum platinum levels could contribute to additional 
nephrotoxicity. Our significant association with follow-up creatinine clearance values may 
therefore be due to low renal function (possibly due to the SNP identified in our GWAS 
intronic to MYH14) raising serum platinum concentrations as well as high serum platinum 
concentrations lowering renal function. One limitation of our study is the lack of baseline 
renal function assessments.
In univariate analysis, the serum platinum phenotype was found to be significantly 
associated with the cumulative morbidity profile and certain toxicities, but robust 
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associations were not detected. Boer et al. (21) identified a significant association with 
neuropathy; however, our dataset indicates that when age is considered, the association with 
neuropathy is no longer statistically significant. Taking age into account, Sprauten et al. (20) 
reported that both paresthesias and Raynaud’s phenomenon were increased two to four-fold 
in the highest quartile of crude serum platinum concentrations. In evaluating categorized 
patients (low, medium, or high residual platinum values), patients with high residual 
platinum values were significantly more likely to have Raynaud’s phenomenon even after 
adjusting for age.
Interestingly, hearing loss and tinnitus appeared to have contrasting levels of association 
with residual platinum values. Although the extent of hearing loss did not appear to be 
associated with residual platinum values, tinnitus did demonstrate a marginal association 
that was independent of age at diagnosis. Further, multinomial regression indicated that 
patients with high levels of serum platinum were more likely to develop tinnitus, suggesting 
these individuals are at an increased risk of developing this off-target toxicity. These data are 
in accord with Hjelle et al. (17) and Sprauten et al. (20) who both found crude serum 
platinum levels to be significantly associated with tinnitus after adjusting for cumulative 
cisplatin dose. Nevertheless, the notable difference in statistical association for hearing loss 
and tinnitus is surprising in light of the fact that concentrations of platinum in the cochlea 
decline much slower than in serum, as cisplatin binding to the cochlea is largely irreversible 
(36). It is plausible that there are differences in the pathophysiology underlying cisplatin-
induced hearing loss and tinnitus, as recent studies have indicated the development of 
tinnitus is more dependent on disruptions in the balance of excitatory and inhibitory nerve 
transmission within central auditory structures than pathology in the cochlea (37). However, 
most investigations of cisplatin-associated ototoxicity have focused on hair cell damage in 
the organ of corti that induces hearing loss (38), and the mechanisms underlying cisplatin-
induced tinnitus are still poorly understood. Therefore, further investigation will be needed 
to discern potential differences regarding the importance of platinum clearance in cisplatin-
induced hearing loss and tinnitus.
Our study relied in large part on patient-reported outcomes in the quantification of platinum 
toxicities. Patient-reported outcomes are increasingly recognized as valid and important and 
enable a broad interrogation of symptoms across conditions in long-term cancer survivors 
(39). Additionally, adverse effects like peripheral neuropathy may not be fully captured with 
objective assessments (40) and may be confounded by physician interpretation on physician-
graded scales (41). An NCI Clinical Trials Planning Meeting (42) recently agreed that self-
report for neuropathy is superior to exam and recommended EORTC-CIPN20. Self-reported 
data may also more adequately quantify the perceived impact on quality of life.
Residual platinum values were also associated with increased LH levels, a finding that has 
been previously noted when assessing either crude serum platinum levels (17) or cumulative 
cisplatin dose (43). Interestingly, residual platinum values were not associated with 
decreased testosterone levels or hypogonadism as in Boer et al. (21), which are often 
observed in TCS due to disturbed endocrine gonadal function that impairs testosterone 
production (17, 43). However, disturbance of endocrine gonadal function in TCS is also 
mediated by other factors such as orchiectomy and testicular dysgenesis syndrome (43). 
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Further, the study that initially reported an association between crude serum platinum and 
LH levels reported no association with testosterone levels (17). Therefore, it is plausible that 
unaccounted variables we have not considered and different phenotype definitions explain 
this discrepancy.
In GWAS, we identified a prominent signal in chromosome 19 in which rs1377817 
(p=4.6×10−8), a SNP intronic to MYH14, met criteria for genome-wide significance, and 
had several other top SNPs in linkage disequilibrium. Importantly, MYH14 encodes for a 
heavy chain that is an integral component of nonmuscle myosin 2, a protein essential for 
kidney development and function (44, 45). When evaluated in mice, Myh14 was expressed 
throughout most segments of the renal tubules, and was implicated in the regulation of the 
renal epithelial transport process (46). Since cisplatin is excreted from the body 
predominantly through renal clearance, the importance of genetic architecture surrounding 
kidney development and function is apparent, and could markedly influence long-term 
platinum kinetics and circulation in serum. Interestingly, a mutation in MYH14 has 
previously been associated with an autosomal dominant disorder of peripheral neuropathy, 
myopathy, hoarseness, and hearing loss (47), indicating that the gene could also potentially 
influence two prominent cisplatin-induced toxicities (peripheral neuropathy and hearing 
loss).
It is important to note that interpretation of genetic results is especially difficult for serum 
platinum, as it is a highly complex phenotype. Contributions of DNA damage-related 
apoptotic pathways, organ development and regeneration, renal function, protein-binding, as 
well as the pharmacokinetic pathways of cisplatin (absorption, distribution, metabolism, and 
excretion) are likely all contributing to serum platinum concentrations, but are difficult to 
measure to enable interpretation of biomolecular mechanisms. A strategy of multiple-tissue 
sampling and measurement of platinum concentration has been evaluated in rodent models 
and has generated important insights (36), but this would be difficult in humans.
To our knowledge, at this point, there is no candidate agent that could significantly reduce 
toxicity without impacting antitumor activity for all cancers treated with cisplatin. Plausible 
detoxifying agents include antioxidants (48, 49) although potential risks must always be 
balanced against benefits. In addition, transporter-mediated uptake can be of importance in 
decreasing off-target toxicities of platinum derivatives and therefore can provide protective 
intervention, without compromising anticancer efficacy (50–52). Sodium thiosulfate was 
recently approved to protect against cisplatin-induced hearing loss in children with localized 
hepatoblastoma (49) and did not hamper therapeutic efficacy in localized hepatoblastoma. 
However, administration of this compound has been shown to reduce overall survival in 
pediatric patients with metastatic cancer, which may greatly hamper its clinical applicability 
(53). Reducing the severity of toxicities and comorbidities associated with cisplatin 
treatment is an important goal, particularly for children and young adults with many decades 
of subsequent life.
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Conclusion
Our study demonstrates the need to adjust for time since treatment and confirms previous 
observations that platinum follows a slow elimination and remains in circulation at 
exceptionally high levels for years after cisplatin treatment. Importantly, residual platinum 
values were associated with several cisplatin-induced toxicities and associated 
comorbidities. In addition, our GWAS identified rs1377817 (p=4.6×10−8), a SNP intronic to 
MYH14, to be associated with residual platinum values, suggesting that genetic variation 
may predispose certain patients to high residual platinum values for years after treatment has 
been completed. The genetic association we report requires replication and validation before 
mechanistic insights can be surmised.
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Translational Relevance
Although curative in many settings, cisplatin can elicit severe, often irreversible toxicities 
that impact long-term survivors’ quality of life. Platinum is detectable in the serum for 
decades after completion of cisplatin-based chemotherapy and it has been hypothesized 
that circulating platinum contributes to the severity and persistence of cisplatin-induced 
toxicities. Results of previous studies have been inconsistent partially due to study 
design, lack of consideration of time since treatment in the modeling, and the use of 
relatively small patient cohorts. Here, we report the largest study to date of serum 
platinum levels in 1,010 testicular cancer survivors, and perform a genome-wide 
association study to assess genetic contributions to these levels. We find that, on average, 
it takes decades for patients to reach normal levels of serum platinum. We find modest 
associations between platinum exposure and toxicities, including tinnitus and Raynaud’s 
phenomenon. If confirmed, our results suggest that reducing circulating platinum levels 
in testicular cancer survivors might hold value as a potential strategy to mitigate selected 
toxicities, and subsequently improve the long-term quality of life in this growing 
population of survivors.
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Figure 1. Population Pharmacokinetic Modeling of Long-Term Serum Platinum Levels.
A) Serum platinum levels from 1,010 TCS were fitted to a bi-exponential model in which 
years since treatment completion was taken into account. Cumulative cisplatin dose was 
taken into account by multiplying the serum platinum levels of 400 ± 15 mg/m2 patients by 
0.75, enabling normalization to 300 ± 15 mg/m2 patients prior to model fitting. B) 
Histogram of multiplicative residuals from the bi-exponential model. C) Residuals were log-
transformed to fit a near normal distribution in order to examine the extent to which residual 
platinum values associate with cisplatin-induced toxicities. The bars denote groups of low, 
medium and high.
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Figure 2. Linear Regression of Residual Platinum Value and Continuous Variables.
Simple linear regression results are presented for A) age at diagnosis, B) creatinine 
clearance, and C) LH levels. R2 and p-values for linear regression are reported for all 
phenotypes. A Spearman rank correlation test (rsp) was also performed on LH levels due to 
its positive skew distribution, and results are shown in panel C. Fitted linear regression lines 
are highlighted in gray and 95% confidence intervals are indicated by the light gray shaded 
regions.
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Figure 3. Distributions of Cisplatin-Induced Toxicities in Testicular Cancer Survivors Based on 
Residual Platinum Value.
The overall distribution of A) CBM score for cisplatin-induced toxicities (p = 0.06), B) 
peripheral sensory neuropathy (PSN; p = 0.02), and C) Raynaud’s phenomenon (p = 0.02) in 
TCS based on having low, medium, and high residual platinum values is provided. Low, 
medium, and high groups reflect ordinal stratifications of residual platinum values based on 
their deviation from the mean: “medium” (regression residuals = 0 ± 1 standard deviation 
[SD]), “low” (residuals < −1 SD), and “high” (residuals > 1 SD). All three toxicities are 
divided into different degrees of severity, as indicated in the legend, with associated 
percentages provided in each panel. Sample sizes for each group are indicated within each 
panel on the x-axis. Differences between the proportions of toxicity severity observed for the 
low, medium, and high residual platinum value groups were evaluated for statistical 
significance through the Cochran-Armitage-Mantel 1df chi-square trend test (54).
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Figure 4. Genome-Wide Association Study of Residual Platinum Value as a Continuous Variable.
A) Manhattan plot of GWAS results reveals one locus meeting genome-wide significance (p 
≤ 5 × 10−8): rs1377817 (p = 4.6 × 10−8). Covariates in the analysis include age at diagnosis 
and 10 genetic principal components accounting for population substructure. B) Quantile-
Quantile plot of GWAS results.
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Table 1.
Clinical and Sociodemographic Characteristics for 1,010 Testicular Cancer Survivors According to Residual 
Platinum Values.
Residual Platinum Value
 Characteristic All Patients (n=1,010) Low (n=118) Medium (n=785) High (n=107)
Age at GCT diagnosis (years)
 Median (range) 31 (15-54) 30 (15-53) 31 (15-54) 35 (16-50)
 <20 70 (6.9%) 16 (13.6%) 49 (6.2%) 5 (4.7%)
 20-29 390 (38.6%) 52 (44.1%) 311 (39.6%) 27 (25.2%)
 30-39 351 (34.8%) 32 (27.1%) 273 (34.8%) 46 (43.0%)
 40-55 199 (19.7%) 18 (15.3%) 152 (19.4%) 29 (27.1%)
Time from diagnosis to clinical evaluation (years)
 Median (range) 4.5 (0.6-35.3) 12.2 (0.6-30.3) 4.3 (0.8-30.6) 3.4 (1.1-35.3)
≤1 4 (0.3%) 2 (1.7%) 2 (0.3%) 0 (0%)
>1 and ≤5 539 (53.4%) 35 (29.7%) 437 (55.7%) 67 (62.6%)
>5 and ≤10 243 (24.1%) 14 (11.9%) 206 (26.2%) 23 (21.5%)
>10 and ≤20 181 (17.9%) 48 (40.7%) 122 (15.5%) 11 (10.3%)
>20 43 (4.3%) 19 (16.1%) 18 (2.3%) 6 (5.6%)
Treatment regimena,b
 BEP 545 (54.0%) 72 (61.0%) 429 (54.7%) 44 (41.1%)
 EP 303 (30.0%) 29 (24.6%) 232 (29.6%) 42 (39.3%)
 VIP 25 (2.5%) 6 (5.1%) 15 (1.9%) 4 (3.7%)
 VeIP 1 (0.1%) 0 (0%) 1 (0.1%) 0 (0%)
 Other (includes cisplatin) 135 (13.4%) 11 (9.3%) 107 (13.6%) 17 (15.9%)
Cumulative cisplatin dose (mg/m2)
 Median (range) 400 (286-414) 400 (292-406) 400 (286-414) 400 (297-400)
 <300 20 (2.0%) 1 (0.9%) 18 (2.3%) 1 (0.9%)
 300 406 (40.2%) 47 (39.8%) 317 (40.4%) 42 (39.3%)
 >300 and <400 28 (2.8%) 5 (4.2%) 21 (2.7%) 2 (1.9%)
 400 548 (54.3%) 64 (54.2%) 422 (53.8%) 62 (57.9%)
 >400 8 (0.8%) 1 (0.9%) 7 (0.9%) 0 (0%)
Audiometrically assessed hearing lossc,d
 None 125 (17.1%) 15 (16.0%) 98 (17.6%) 12 (15.4%)
 Mild 162 (22.2%) 17 (18.1%) 127 (22.8%) 18 (23.1%)
 Moderate 111 (15.2%) 18 (19.1%) 81 (14.5%) 12 (15.4%)
 Moderately severe 154 (21.1%) 17 (18.1%) 122 (21.9%) 15 (19.2%)
 Severe/profound 178 (24.4%) 27 (28.7%) 130 (23.3%) 21 (26.9%)
Tinnituse
 Yes 355 (37.2%) 38 (33.0%) 271 (36.7%) 46 (45.5%)
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Residual Platinum Value
 Characteristic All Patients (n=1,010) Low (n=118) Medium (n=785) High (n=107)
 No 599 (62.8%) 77 (67.0%) 467 (63.3%) 55 (54.5%)
Peripheral sensory neuropathyf,g
 None 429 (43.1%) 52 (44.1%) 343 (45.3%) 9 (9.5%)
 A little 472 (47.4%) 57 (48.3%) 361 (47.6%) 69 (72.6%)
 Quite a bit/very much 95 (9.5%) 9 (7.6%) 54 (7.1%) 17 (17.9%)
Raynaud’s phenomenong,h
 None 634 (64.0%) 80 (67.8%) 497 (64.5%) 57 (55.3%)
 A little 205 (20.7%) 27 (22.9%) 154 (20.0%) 24 (23.3%)
 Quite a bit/very much 152 (15.3%) 11 (9.3%) 119 (15.5%) 22 (21.4%)
Abbreviations: BEP: bleomycin, etoposide, and cisplatin; EP: etoposide and cisplatin; VIP: etoposide, ifosfamide, and cisplatin; VeIP: vinblastine, 
ifosfamide, and cisplatin
aBEP category includes patients who received only bleomycin, etoposide, and cisplatin; EP includes patients who received only etoposide and 
cisplatin; VIP includes patients who received only etoposide, ifosfamide, and cisplatin; VeIP includes patients who received only vinblastine, 
ifosfamide, and cisplatin. The other category includes patients who received an unspecified cisplatin-based treatment regimen.
b1 participant was missing data for treatment regimen.
c280 participants did not have hearing assessed audiometrically.
dASHA criteria defined hearing loss severity as the following: mild: 21 to 40 dB; moderate: 41 to 55 dB; moderately severe: 56 to 70 dB; severe: 
71 to 90 dB; and profound: > 90 dB; for at least one tested frequency for either ear (https://www.asha.org/public/hearing/Degree-of-Hearing-Loss).
e56 participants did not report tinnitus status.
f14 participants did not report peripheral sensory neuropathy status.
g
Following conversion of the Likert scale: “none, a little, quite a bit, very much” to a 0-3 numeric scale, each individual was attributed a summary 
statistic for the sensory subscale (Cronbach α = 0.88) and the motor subscale (α = 0.78) by taking the mean of the response in the subscale: none 
(mean = 0), mild (0 < mean ≤ 1), severe (mean > 1), as in Dolan et al (9).
h19 participants did not report Raynaud’s phenomenon status.
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s i
n D
ola
n e
t a
l (
9).
f D
ef
in
ed
 b
y 
th
e 
ra
nk
 n
or
m
al
iz
ed
 g
eo
m
et
ric
 m
ea
n 
of
 a
ir 
co
nd
uc
tio
n 
th
re
sh
ol
ds
 m
ea
su
re
d 
at
 4
, 6
, 8
, 1
0,
 an
d 
12
 k
H
z, 
as
 in
 F
ris
in
a e
t a
l (
7).
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